Psoriasis – Epidemiology – Mature Markets

Clarivate Epidemiology's coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries covered in this report.

Clarivate Epidemiology's PsO forecast will answer the following questions:

  • Of all people diagnosed with PsO, how many in each country across the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PsO over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 11 PsO patient populations, as follows:

  • Diagnosed PsO prevalent cases
  • Diagnosed mild PsO prevalent cases
  • Diagnosed moderate PsO prevalent cases
  • Diagnosed severe PsO prevalent cases
  • Diagnosed moderate to severe PsO prevalent cases
  • Diagnosed moderate PsO drug-treated prevalent cases
  • Diagnosed severe PsO drug-treated prevalent cases
  • Diagnosed plaque PsO prevalent cases
  • … and many more (details available on request).

Note: coverage may vary by country.

Table of contents

  • Psoriasis - Epidemiology - Mature Markets
    • Epidemiology Data
    • Methods
      • Literature review (studies included in / excluded from the analyses of psoriasis)
      • Diagnosed prevalent cases
      • Diagnosed prevalent cases by severity
      • Diagnosed Drug-Treated Prevalent Cases by Severity
      • Diagnosed prevalent cases by subtype
      • Risk / protective factors applied to disease forecast models
    • Reference materials
      • Bibliography
      • Glossary
      • Abbreviations

Login to access report